AKT1 and neoplasm: As tumor detection and mortality rates have slowly changed over the past decade, an enhanced vigor in therapeutic targets have revolved around the PI3K-AKT pathway for cancer drug discovery [58–60], specifically with the addition of genomic studies [61].